Australia's most trusted
source of pharma news
Friday, 23 January 2026
Posted 21 January 2026 AM
Eli Lilly has joined Novo Nordisk in discontinuing some of its own insulin products from the Australian market, with the latter also providing an update on the availability of its insulin offerings.
The vial presentations of Lilly’s Humalog, Humulin R vials, Humulin NPH, and Humulin 30/70 are set to be discontinued from August. Alternative presentations of these insulins are expected to remain available, including KwikPen and cartridge dose forms.

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.